Company / Accounts Receivable
TREACE MEDICAL CONCEPTS, INC. Accounts Receivable History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$42.2M
FY2025
5-year range
$18.6M / $42.2M
FY2021-FY2025
Trend
+10.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $38M to $42M over the past 2 years.
Based on SEC 10-K filings.
$42M in FY2025 with a 3-year CAGR of +13.0%.
Improved from $38M to $42M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +13.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +13.0%, indicating consistent growth.
- In FY2025, accounts receivable increased 10.8% year-over-year.
- Lowest accounts receivable in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $42.2M | +10.8% |
| FY2024 | $38.1M | +0.0% |
| FY2023 | $38.1M | +30.4% |
| FY2022 | $29.2M | +57.2% |
| FY2021 | $18.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026